Developer docs
API playgroundTry for free, no card

Search company profiles

Aegle Therapeutics

Full company profile

uuid0000dz9

Namestring
Aegle Therapeutics
Legal namestring
Aegle Therapeutics Corp.
Company typeenum
Private
Founded yearint
2015
Descriptiontext

Aegle Therapeutics is a clinical-stage biotechnology company developing cell-free extracellular vesicle (EV) therapies derived from bone marrow mesenchymal stem cells (MSCs). Founded in 2015 and headquartered in Woburn, Massachusetts with an additional office in Miami, Florida, the company focuses on rare dermatological and immunologic diseases with significant unmet medical need. Its lead product candidate AGLE-102™ is a therapeutic composite of MSC-derived EVs, including exosomes, carrying COL7 protein and COL7A1 mRNA designed to induce collagen VII production in patients with Recessive Dystrophic Epidermolysis Bullosa (RDEB), a rare pediatric monogenetic disorder causing severe skin blistering, disfigurement, and shortened lifespan.

The platform is built on a proprietary EV harvesting technology exclusively licensed from the University of Miami that isolates EVs from MSCs without damaging or modifying them, an approach that distinguishes Aegle from conventional EV isolation methods that can trigger inflammatory responses. AGLE-102 is currently in a Phase 1/2 clinical trial (NCT04173650) for RDEB, with the first patient dosed in August 2024. The pipeline also includes a completed pilot study in severe burns (NCT05078385) funded by a U.S. Department of Defense CDMRP grant, and preclinical work in Graft versus Host Disease prophylaxis. Aegle has received FDA IND clearance for both burn (2018) and DEB (2019) indications, plus Rare Pediatric Disease Designation and Fast Track Status for AGLE-102 in October 2020.

As a pre-revenue company, Aegle generates no commercial product sales and relies on equity and debt financings to fund operations. Disclosed funding to date includes a $4M financing (January 2020), a $6.5M Series A (September 2020), a $3M DeepWork Capital investment (April 2022), and a $700K debt offering (March 2026), aggregating roughly $10.5M-$14.2M. Upon FDA approval, the company plans to commercialize through traditional pharmaceutical channels including specialty pharmacies and hospital systems, targeting orphan/rare disease pricing economics. The company is led by CEO Shelley Hartman (former Goldman Sachs Managing Director), Founder/CSO Dr. Evangelos Badiavas (a board-certified dermatologist with three FDA INDs), and Chairman Dr. Scott Braunstein (former CEO of Marinus Pharmaceuticals, sold to Immedica Pharma).

Short descriptiontext

Aegle Therapeutics is a clinical-stage biotech developing AGLE-102, a first-in-class MSC-derived extracellular vesicle therapy for rare pediatric diseases, with its lead program in Phase 1/2 trials for Recessive Dystrophic Epidermolysis Bullosa.

Operating statusenum
Operating
Ownership categoryenum
Headcount rangeband
1–10
akta.pro rankint
HeadquartersWoburn, United States
HQ citystring
Woburn
HQ countrystring
United States
HQ regionstring
North America
Markets served

Serves global market

Offices2 records

Each record includes

City, Country, Type, Description, Source

Keyword5 values
regenerative medicine therapeutics, extracellular vesicle therapy, rare disease biopharmaceuticals, stem cell-derived exosomes, cell-free biologics
Industry3 codes
PRIMARYHLAAAGAA
Stem Cell–Based Regenerative Therapies
Healthcare & Life Sciences/Biotechnology & Biologics/Regenerative Medicine & Tissue Engineering
SECONDARYHLAIAIAN
Rare Pediatric & Congenital Disorder Therapies
Healthcare & Life Sciences/Pharmaceuticals/Orphan & Rare Disease Pharmaceuticals
SECONDARYHLAAABAE
Stem Cell Therapies (MSC/iPSC/HSC-derived)
Healthcare & Life Sciences/Biotechnology & Biologics/Cell Therapy (autologous/allogeneic)
NAICS code2 codes
  • Biological Product (except Diagnostic) Manufacturing325414
  • Research and Development in Biotechnology (except Nanobiotechnology)541714
SIC code1 code
  • Biological Products, (No Disgnostic Substances)2836
Product category
Regenerative Medicine Biologics
Social media profiles1 record
GTM motion1 record

Each record includes

Type, Description, Source

Revenue model1 record
1Pharmaceutical/Biologic Product Sales
TypeOne Time License
Description

Pre-revenue clinical stage company. Upon FDA approval of AGLE-102 and future pipeline products, revenue will be generated through sales of FDA-approved biologic therapies for rare diseases including dystrophic epidermolysis bullosa and other dermatological disorders.

aegletherapeutics.com
Marketing channels5 records

Each record includes

Title, Type, Stage, Description, Source

Distribution channels1 record

Each record includes

Title, Type, Scope, Target buyer, Description, Source

Cost components5 values
Technology or R&D, Personnel, Operations, Marketing or Sales, Infrastructure
GTM typeB2B
B2B
Offering typeHardware or Manufacturing
Hardware or Manufacturing
Core offering1 text field

Aegle Therapeutics is a clinical-stage biopharmaceutical company developing cell-free extracellular vesicle (EV) therapies derived from bone marrow mesenchymal stem cells (MSCs). Its lead product AGLE-102 is in Phase 1/2 clinical trials for Recessive Dystrophic Epidermolysis Bullosa (RDEB), with additional programs in severe burns and Graft vs. Host Disease. The proprietary platform delivers natural biomolecular payloads including COL7 protein and COL7A1 mRNA to diseased and damaged cells for regenerative treatment of rare dermatological and immunological disorders.

Differentiator
Functional benefit
Problem solved
Quantifiable outcome1 of 3 values shown
  • Phase 1/2 clinical trial for RDEB now enrolling with positive first patient data announced January 2024
+2 more records
Product overview1 text field

Aegle Therapeutics is a clinical-stage biotechnology company developing a single unified therapeutic platform based on mesenchymal stem cell (MSC)-derived extracellular vesicles (EVs). The lead product AGLE-102™ is a first-in-class EV therapy currently in Phase 1/2a clinical trials for Recessive Dystrophic Epidermolysis Bullosa (RDEB), with additional programs in burns (completed pilot study) and Graft vs. Host Disease (preclinical). The company leverages its proprietary EV harvesting technology, exclusively licensed from the University of Miami, to produce cell-free therapies that deliver therapeutic biomolecules to diseased and damaged cells.

Product and service2 records
1AGLE-102
CategoryCell-free biologic therapy (extracellular vesicle therapy)
Description

AGLE-102 is a first-in-class therapeutic composite of extracellular vesicles (EVs), including exosomes, isolated from bone marrow-derived mesenchymal stem cells (MSCs) using Aegle's proprietary EV harvesting technology. It contains COL7 protein as well as COL7A1 mRNA and is designed to treat Recessive Dystrophic Epidermolysis Bullosa (RDEB) by inducing fibroblasts to produce COL7 and promote functional skin tissue regeneration. It is non-immunogenic and carries immunomodulating and anti-inflammatory properties.

2MSC-Derived Extracellular Vesicle (EV) Therapy Platform
CategoryRegenerative medicine technology platform
Description

The MSC-Derived Extracellular Vesicle (EV) Therapy Platform is Aegle's proprietary technology platform that isolates EVs from bone marrow-derived mesenchymal stem cells without damaging or modifying the vesicles, using patented harvesting technology exclusively licensed from the University of Miami. It harnesses the regenerative, immunomodulatory, and anti-inflammatory properties of MSC-derived EVs to deliver natural biomolecular payloads (proteins, microRNAs, messenger RNAs, and skin basement membrane proteins such as collagen IV and collagen VII) to treat disorders with significant unmet medical need.

Scale indicator6 records

Each record includes

Type, Value, Description, Source

Partnership1 partner
Strategic tierCoreTypeStrategic or Co-development Partner
Description

University of Miami exclusively licensed Aegle's patented EV harvesting technology. Dr. Evangelos Badiavas, Founder and CSO, has research history with the University of Miami. Aegle has published research conducted in collaboration with University of Miami researchers on wound healing and stem cell-derived EVs.

Recent move6 records

Each record includes

Date, Type, Title, Description, Source

Expansion highlight5 records

Each record includes

Type, Description

Peers10 records
TypeDirect peer
Description

Clinical-stage biotech developing exosome/EV-based therapeutics (deramiocel, lead asset for Duchenne muscular dystrophy) using cardiosphere-derived cell EVs. Closest direct peer to Aegle given shared EV/exosome modality and rare-disease focus, though with a different therapeutic area.

TypeDirect peer
Description

Commercial-stage biotech whose lead product Vyjuvek is an FDA-approved topical gene therapy for DEB. Directly competes with AGLE-102 in the same patient population and represents the benchmark Aegle must beat on efficacy, convenience, and durability.

TypeDirect peer
Description

Develops cell and gene therapies for rare diseases including recessive DEB (EB-101 was approved by FDA as Zevaskyn in 2025). Direct DEB competitor to AGLE-102 with overlapping patient population and similar rare-disease commercial dynamics.

TypeEmerging player
Description

Late-stage cell- and gene-therapy developer for rare dermatological diseases including DEB (dabocemagene autoficel). Competes with AGLE-102 in the same DEB patient segment using a different (autologous gene-modified cell) modality.

TypeDirect peer
Description

UK-based developer of engineered exosome therapeutics (e.g., for rare metabolic and CNS indications). Closest modality peer to Aegle's MSC-EV platform with comparable exosome engineering and proprietary isolation IP.

TypeDirect peer
Description

South Korea-based clinical-stage developer of exosome-based therapeutics for atopic dermatitis, sepsis, and rare diseases. Directly comparable to Aegle in modality (exosome therapeutics) and overlap in dermatology indications.

TypeDirect peer
Description

Clinical-stage regenerative medicine company developing bone marrow MSC-derived EV products (ExoFlo) for inflammatory and regenerative indications including wound healing. Comparable to Aegle in MSC-EV platform and overlapping wound/burn use cases.

TypeEmerging player
Description

Preclinical/early-clinical developer of a recombinant collagen VII protein therapy for RDEB. Competes with AGLE-102 in the same COL7-deficient patient population using a different (recombinant protein) approach — useful comparator for evaluating AGLE-102's clinical and commercial profile.

TypeOthers
Description

Supplier of human MSC and EV products and manufacturing platforms used by regenerative medicine developers. Comparable because RoosterBio's MSC-EV raw material and process technology is an enabling input for any MSC-EV therapeutic including Aegle's platform.

TypeEmerging player
Description

Clinical-stage developer of engineered exosome-based therapeutics (e.g., ILB-001 for sepsis-related inflammatory disease). Comparable modality to Aegle with overlapping anti-inflammatory/immunomodulatory mechanism of action derived from EV/exosome biology.

Market position
Strengths5 records

Each record includes

Headline, Details, Source

Weaknesses5 records

Each record includes

Headline, Details, Source

Competitive moat4 records

Each record includes

Type, Details

Key risks6 records

Each record includes

Headline, Details, Source

Key highlights7 records

Each record includes

Headline, Details, Source

Customer concentration

Classification, Details

Segment3 records

Each record includes

Title, Type, Primary, Description, Pain point addressed, Use case, Source

Ideal customer profile2 records

Each record includes

Profile, Firmographic size, Sales motion, Sales cycle length, Buying structure, Purchase trigger, Buyer persona, Geography, Industry vertical, Primary use case, Description, Pain points, Evidence proof points, Target buyer

Technology focused
Yes
API detail
Has APIbool
No

Docs URL, Description

AI maturity
App detail

Has app

Feature3 records

Each record includes

Title, Differentiator, Description, Source

Core technology
Revenue estimate
Valuation estimate
Number of profiles
Profiles9 records

Each record includes

Name, Designation, Designation category, Overview, Profile commentary, Source

No data
No data
Funding overview

Funding stage, Last funding date, Total funding USD

Funding rounds6 records

Each record includes

Round, Amount USD, Date, Pre money valuation, Total investors, Investors, News

Investors6 records

Each record includes

Name, Type, Date of entry, Rounds participated, Website

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Each record includes

Name, Acquisition type, Announced date, Completed date, Status, Website, News

Investment

Each record includes

Name, Round, Announced date, Lead investor, Website, News

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Aegle Therapeutics

Regenerative Medicine Biologicsaegletherapeutics.com

Aegle Therapeutics is a clinical-stage biotech developing AGLE-102, a first-in-class MSC-derived extracellular vesicle therapy for rare pediatric diseases, with its lead program in Phase 1/2 trials for Recessive Dystrophic Epidermolysis Bullosa.

What Aegle Therapeutics does

Aegle Therapeutics is a clinical-stage biotechnology company developing cell-free extracellular vesicle (EV) therapies derived from bone marrow mesenchymal stem cells (MSCs). Founded in 2015 and headquartered in Woburn, Massachusetts with an additional office in Miami, Florida, the company focuses on rare dermatological and immunologic diseases with significant unmet medical need. Its lead product candidate AGLE-102™ is a therapeutic composite of MSC-derived EVs, including exosomes, carrying COL7 protein and COL7A1 mRNA designed to induce collagen VII production in patients with Recessive Dystrophic Epidermolysis Bullosa (RDEB), a rare pediatric monogenetic disorder causing severe skin blistering, disfigurement, and shortened lifespan.

The platform is built on a proprietary EV harvesting technology exclusively licensed from the University of Miami that isolates EVs from MSCs without damaging or modifying them, an approach that distinguishes Aegle from conventional EV isolation methods that can trigger inflammatory responses. AGLE-102 is currently in a Phase 1/2 clinical trial (NCT04173650) for RDEB, with the first patient dosed in August 2024. The pipeline also includes a completed pilot study in severe burns (NCT05078385) funded by a U.S. Department of Defense CDMRP grant, and preclinical work in Graft versus Host Disease prophylaxis. Aegle has received FDA IND clearance for both burn (2018) and DEB (2019) indications, plus Rare Pediatric Disease Designation and Fast Track Status for AGLE-102 in October 2020.

As a pre-revenue company, Aegle generates no commercial product sales and relies on equity and debt financings to fund operations. Disclosed funding to date includes a $4M financing (January 2020), a $6.5M Series A (September 2020), a $3M DeepWork Capital investment (April 2022), and a $700K debt offering (March 2026), aggregating roughly $10.5M-$14.2M. Upon FDA approval, the company plans to commercialize through traditional pharmaceutical channels including specialty pharmacies and hospital systems, targeting orphan/rare disease pricing economics. The company is led by CEO Shelley Hartman (former Goldman Sachs Managing Director), Founder/CSO Dr. Evangelos Badiavas (a board-certified dermatologist with three FDA INDs), and Chairman Dr. Scott Braunstein (former CEO of Marinus Pharmaceuticals, sold to Immedica Pharma).

Aegle Therapeutics firmographics

Firmographics
Name
Aegle Therapeutics
Legal name
Aegle Therapeutics Corp.
Website
https://aegletherapeutics.com
Company type
Private
Founded year
2015
Operating status
Operating
Headcount range
1–10 employees
Short description
Aegle Therapeutics is a clinical-stage biotech developing AGLE-102, a first-in-class MSC-derived extracellular vesicle therapy for rare pediatric diseases, with its lead program in Phase 1/2 trials for Recessive Dystrophic Epidermolysis Bullosa.
Ownership category
akta.pro rank

Aegle Therapeutics industry classification

Industry
Product category
Regenerative Medicine Biologics
NAICS
Biological Product (except Diagnostic) Manufacturing (325414), Research and Development in Biotechnology (except Nanobiotechnology) (541714)
SIC
Biological Products, (No Disgnostic Substances) (2836)
akta.pro industry
PRIMARYHLAAAGAA
Stem Cell–Based Regenerative Therapies
Healthcare & Life Sciences/Biotechnology & Biologics/Regenerative Medicine & Tissue Engineering
SECONDARYHLAIAIAN
Rare Pediatric & Congenital Disorder Therapies
Healthcare & Life Sciences/Pharmaceuticals/Orphan & Rare Disease Pharmaceuticals
SECONDARYHLAAABAE
Stem Cell Therapies (MSC/iPSC/HSC-derived)
Healthcare & Life Sciences/Biotechnology & Biologics/Cell Therapy (autologous/allogeneic)

Keywords

  • Regenerative medicine therapeutics
  • Extracellular vesicle therapy
  • Rare disease biopharmaceuticals
  • Stem cell-derived exosomes
  • Cell-free biologics

Where Aegle Therapeutics is headquartered

Location

Headquarters

HQ city
Woburn
HQ country
United States
HQ region
North America

Offices2 records

Markets served

Aegle Therapeutics business model

Business model
GTM type
B2B
Offering type
Hardware or Manufacturing
Cost components
Technology or R&D, Personnel, Operations, Marketing or Sales, Infrastructure

Revenue model

  1. Pharmaceutical/Biologic Product Sales: Pre-revenue clinical stage company. Upon FDA approval of AGLE-102 and future pipeline products, revenue will be generated through sales of FDA-approved biologic therapies for rare diseases including dystrophic epidermolysis bullosa and other dermatological disorders.

Go-to-market motion1 record

Distribution channels1 record

Marketing channels5 records

Aegle Therapeutics product offering

Product offering

Core offering

Aegle Therapeutics is a clinical-stage biopharmaceutical company developing cell-free extracellular vesicle (EV) therapies derived from bone marrow mesenchymal stem cells (MSCs). Its lead product AGLE-102 is in Phase 1/2 clinical trials for Recessive Dystrophic Epidermolysis Bullosa (RDEB), with additional programs in severe burns and Graft vs. Host Disease. The proprietary platform delivers natural biomolecular payloads including COL7 protein and COL7A1 mRNA to diseased and damaged cells for regenerative treatment of rare dermatological and immunological disorders.

Product overview

Aegle Therapeutics is a clinical-stage biotechnology company developing a single unified therapeutic platform based on mesenchymal stem cell (MSC)-derived extracellular vesicles (EVs). The lead product AGLE-102™ is a first-in-class EV therapy currently in Phase 1/2a clinical trials for Recessive Dystrophic Epidermolysis Bullosa (RDEB), with additional programs in burns (completed pilot study) and Graft vs. Host Disease (preclinical). The company leverages its proprietary EV harvesting technology, exclusively licensed from the University of Miami, to produce cell-free therapies that deliver therapeutic biomolecules to diseased and damaged cells.

Differentiator

Problem solved

Functional benefit

Products and services

  • AGLE-102 AGLE-102 is a first-in-class therapeutic composite of extracellular vesicles (EVs), including exosomes, isolated from bone marrow-derived mesenchymal stem cells (MSCs) using Aegle's proprietary EV harvesting technology. It contains COL7 protein as well as COL7A1 mRNA and is designed to treat Recessive Dystrophic Epidermolysis Bullosa (RDEB) by inducing fibroblasts to produce COL7 and promote functional skin tissue regeneration. It is non-immunogenic and carries immunomodulating and anti-inflammatory properties.
  • MSC-Derived Extracellular Vesicle (EV) Therapy Platform The MSC-Derived Extracellular Vesicle (EV) Therapy Platform is Aegle's proprietary technology platform that isolates EVs from bone marrow-derived mesenchymal stem cells without damaging or modifying the vesicles, using patented harvesting technology exclusively licensed from the University of Miami. It harnesses the regenerative, immunomodulatory, and anti-inflammatory properties of MSC-derived EVs to deliver natural biomolecular payloads (proteins, microRNAs, messenger RNAs, and skin basement membrane proteins such as collagen IV and collagen VII) to treat disorders with significant unmet medical need.

Quantifiable outcome

  • Phase 1/2 clinical trial for RDEB now enrolling with positive first patient data announced January 2024
  • +2 more outcomes

Companies that use Aegle Therapeutics

Customer profile

Segments3 records

Ideal customer profiles2 records

Aegle Therapeutics technology and API

Technology

Technology focussed Yes

API detail

Has API
No
API docs
API detail

Core technology

AI maturity

App detail

Feature3 records

Aegle Therapeutics partnerships and signals

Strategic signal

Partnerships

One partnership is on record.

  • University of MiamicoreStrategic or Co-development PartnerUniversity of Miami exclusively licensed Aegle's patented EV harvesting technology. Dr. Evangelos Badiavas, Founder and CSO, has research history with the University of Miami. Aegle has published research conducted in collaboration with University of Miami researchers on wound healing and stem cell-derived EVs.

Scale indicators6 records

Recent moves6 records

Expansion highlights5 records

Aegle Therapeutics competitors and assessment

Company assessment

Direct peers

  • Capricor Therapeutics: Clinical-stage biotech developing exosome/EV-based therapeutics (deramiocel, lead asset for Duchenne muscular dystrophy) using cardiosphere-derived cell EVs. Closest direct peer to Aegle given shared EV/exosome modality and rare-disease focus, though with a different therapeutic area.
  • Krystal Biotech: Commercial-stage biotech whose lead product Vyjuvek is an FDA-approved topical gene therapy for DEB. Directly competes with AGLE-102 in the same patient population and represents the benchmark Aegle must beat on efficacy, convenience, and durability.
  • Abeona Therapeutics: Develops cell and gene therapies for rare diseases including recessive DEB (EB-101 was approved by FDA as Zevaskyn in 2025). Direct DEB competitor to AGLE-102 with overlapping patient population and similar rare-disease commercial dynamics.
  • Evox Therapeutics: UK-based developer of engineered exosome therapeutics (e.g., for rare metabolic and CNS indications). Closest modality peer to Aegle's MSC-EV platform with comparable exosome engineering and proprietary isolation IP.
  • ExoCoBio: South Korea-based clinical-stage developer of exosome-based therapeutics for atopic dermatitis, sepsis, and rare diseases. Directly comparable to Aegle in modality (exosome therapeutics) and overlap in dermatology indications.
  • Direct Biologics: Clinical-stage regenerative medicine company developing bone marrow MSC-derived EV products (ExoFlo) for inflammatory and regenerative indications including wound healing. Comparable to Aegle in MSC-EV platform and overlapping wound/burn use cases.

Emerging players

  • Castle Creek Biosciences: Late-stage cell- and gene-therapy developer for rare dermatological diseases including DEB (dabocemagene autoficel). Competes with AGLE-102 in the same DEB patient segment using a different (autologous gene-modified cell) modality.
  • Phoenix Tissue Repair: Preclinical/early-clinical developer of a recombinant collagen VII protein therapy for RDEB. Competes with AGLE-102 in the same COL7-deficient patient population using a different (recombinant protein) approach — useful comparator for evaluating AGLE-102's clinical and commercial profile.
  • Ilias Biologics: Clinical-stage developer of engineered exosome-based therapeutics (e.g., ILB-001 for sepsis-related inflammatory disease). Comparable modality to Aegle with overlapping anti-inflammatory/immunomodulatory mechanism of action derived from EV/exosome biology.

Others

  • RoosterBio: Supplier of human MSC and EV products and manufacturing platforms used by regenerative medicine developers. Comparable because RoosterBio's MSC-EV raw material and process technology is an enabling input for any MSC-EV therapeutic including Aegle's platform.

Market position

Strengths5 records

Weaknesses5 records

Competitive moat4 records

Key risks6 records

Key highlights7 records

Customer concentration

Aegle Therapeutics social profiles

Digital presence

Aegle Therapeutics financial estimates

Financial estimate

Revenue estimate

Valuation estimate

Aegle Therapeutics leadership team

Management profile

Number of profiles

Profiles9 records

Aegle Therapeutics funding detail

Funding detail

Funding overview

Funding rounds6 records

Investors6 records

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

Aegle Therapeutics M&A and investment

M&A and investment

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Aegle Therapeutics

What does Aegle Therapeutics do?

Aegle Therapeutics is a clinical-stage biopharmaceutical company developing cell-free extracellular vesicle (EV) therapies derived from bone marrow mesenchymal stem cells (MSCs). Its lead product AGLE-102 is in Phase 1/2 clinical trials for Recessive Dystrophic Epidermolysis Bullosa (RDEB), with additional programs in severe burns and Graft vs. Host Disease. The proprietary platform delivers natural biomolecular payloads including COL7 protein and COL7A1 mRNA to diseased and damaged cells for regenerative treatment of rare dermatological and immunological disorders.

Is Aegle Therapeutics a public or private company?

Aegle Therapeutics is a private company. It is classified as venture growth investor backed and is currently operating.

When was Aegle Therapeutics founded?

Aegle Therapeutics was founded in 2015. It employs 1 to 10 people.

Where is Aegle Therapeutics based?

Aegle Therapeutics is headquartered in Woburn, United States, in the North America region.

How does Aegle Therapeutics make money?

One revenue line is on record: pharmaceutical/Biologic Product Sales.

Who are Aegle Therapeutics's main competitors?

Direct peers on record are Capricor Therapeutics, Krystal Biotech, Abeona Therapeutics, Evox Therapeutics, ExoCoBio and Direct Biologics. Emerging players are Castle Creek Biosciences, Phoenix Tissue Repair and Ilias Biologics. RoosterBio is listed as an others.

Does Aegle Therapeutics have an API?

No public API is recorded for Aegle Therapeutics.

What industry is Aegle Therapeutics in?

Aegle Therapeutics's product category is Regenerative Medicine Biologics. Its primary akta.pro industry code is HLAAAGAA, Stem Cell–Based Regenerative Therapies, with a secondary code of HLAIAIAN, Rare Pediatric & Congenital Disorder Therapies. Its NAICS code is 325414 and its SIC code is 2836.

Unlock the full company data

50 free credits on sign-up, no credit card required.

Contact sales
Live signals
Delveinsight5 Exosome Therapies in the Clinical PipelineDelveInsight has published an industry overview highlighting five exosome-based therapies currently in clinical development, including Deramiocel (Capricor Therapeutics/Nippon Shinyaku), ExoFlo (Direct Biologics), AGLE-102 (Aegle Therapeutics), BRE-AD01 (Brexogen), and ILB-202 (ILIAS Biologics). Capricor's Deramiocel for Duchenne muscular dystrophy has reached a critical milestone with an FDA PDUFA target date of August 22, 2026, following resumption of its Biologics License Application review. The article also profiles emerging developers such as Aruna Bio, NurExone Biologic, and VivaZome Therapeutics advancing exosome candidates for neurological conditions, while noting that no exosome-based therapy has yet received FDA approval.SecSEC FORM DAegle Therapeutics Corp, a Delaware-incorporated biotechnology company headquartered in Woburn, Massachusetts, filed a Form D notice with the SEC on March 3, 2026, for an exempt offering of debt securities under Rule 506(b) and 506(c) exemptions.openPR.comExosome Therapeutics Pipeline Insights Industry Intelligence: Clinical Trials, Approvals & Emerging TherapiesDataM Intelligence published a market research report on the exosome therapeutics pipeline, covering clinical trials, approvals, and emerging therapies. Key developments include Rion's Phase II trial for diabetic foot ulcers, AEGLE's Phase I/II for epidermolysis bullosa, and Direct Biologics' Phase III for ARDS. The market is projected to grow from 2025 to 2032.GlobeNewswireAegle Therapeutics Names Industry Veteran Scott Braunstein, M.D. as Chairman of the BoardAegle Therapeutics appointed Scott Braunstein, M.D., as chairman of the board. The company's lead product candidate AGLE-102 is in a Phase 1/2a trial for recessive dystrophic epidermolysis bullosa. Braunstein brings over 30 years of industry experience from roles at Marinus Pharmaceuticals and Pacira Pharmaceuticals.openPR.comAI in Clinical Trials Market Growth 2025: Trends, Consumer Demand, and Key Opportunities | Aegle Therapeutics, Coya Therapeutics, Evox TherapeuticsThe global AI in clinical trials market is projected to grow from USD 1.77 billion in 2025 to USD 5.12 billion by 2032, a CAGR of 16.4%. The report identifies Aegle, Coya, and Evox Therapeutics as key players and segments the market by offering, technology, application, and end user.BioinformantExosomes as a Burgeoning New Frontier in Cell-Free TherapeuticsStem cell companies are increasingly shifting focus to exosome therapeutics as a response to the commercialization challenges faced by traditional stem cell therapies. Several companies, including Aegle Therapeutics, Exopharm Ltd, and United Therapeutics, are currently conducting clinical trials for exosome-based treatments, with potential applications in various medical conditions. The rise in exosome research and clinical trials suggests a growing market for these cell-free therapeutics.PR NewswireAegle Therapeutics Corp. Announces Positive Data for the First Patient in a Phase 1/2a Clinical Trial Dosed With AGLE-102™, a Novel Extracellular Vesicle TherapyAegle Therapeutics Corp. announced positive 12-week data for the first patient treated with AGLE-102 in a Phase 1/2a clinical trial for severe second-degree burns. The patient achieved 99% epithelialization of the burn wound within seven days after receiving a single dose, with no safety issues reported. This milestone underscores the potential of AGLE-102 as a novel therapy for severe dermatological conditions.BiopharmiqList of Regenerative Medicine Companies in United StatesA compiled directory lists dozens of United States-based regenerative medicine and cell therapy companies, including Abeona Therapeutics, Aegle Therapeutics, Alkahest, AllCells, Amnio Technology, Axogen, BICO, and BioCardia. Entries describe each firm's location, stage, product pipeline, and key technologies such as extracellular vesicles, Wnt proteins, bioinks, and amnion-derived materials.PR NewswireAegle Therapeutics Corp. Announces First Patient Dosed in Phase 1/2a Clinical Trial Administering a Novel Extracellular Vesicle TherapyAegle Therapeutics announced the first patient has been dosed in its Phase 1/2a clinical trial of AGLE-102, an extracellular vesicle therapy for severe second-degree burns. The trial evaluates safety and efficacy of multiple administrations, with a phase 1/2a study for epidermolysis bullosa anticipated in Q4 2023.ZapierAegle Therapeutics’ big mission: Tackling a horrific pediatric disorderAegle Therapeutics is developing a cell-free treatment for dystrophic epidermolysis bullosa (DEB), a rare genetic pediatric disorder, following the closure of its $6.5 million Series A funding round in September 2020. The company plans to initiate phase 1/2a clinical trials in 2021 to test the safety and efficacy of this proprietary approach derived from Dr. Evangelos Badiavas's research.